OSE Immunotherapeutics Adds Boehringer Ingelheim To Its Pharma Partnering List
Collaborating with the German family-controlled drug maker on OSE's novel checkpoint inhibitor aligns with French firm's strategy of partnering its portfolio candidates.
You may also be interested in...
Boehringer Ingelheim intends to combine Lupin’s MEK inhibitor with its own KRAS inhibitors to target the oncogenic KRAS-RAF-MEK-ERK pathway, mutations in which drive many difficult-to-treat cancers.
Boehringer Ingelheim’s US business development head Ioannis Sapountzis outlines BI’s efforts to catch up with competitors in NASH and immuno-oncology via early-stage partnerships and licensing deals.